Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This, international, multi-center, Phase 2 study of verubulin will be conducted in patients
with newly diagnosed Glioblastoma Multiforme (GBM). The study will be conducted in two parts.
Part A is an open-label dose finding study that will determine the safety and tolerability of
verubulin in combination with standard treatment. Part B is a randomized open-label study
that will investigate progression-free survival and overall survival of patients receiving
verubulin, at the dose determined in Part A, in combination with standard treatment versus
standard treatment alone.